A Complete Study of Farrerol Metabolites Produced In Vivo and In Vitro

Yin, Jun; Ma, Yinling; Liang, Caijuan; Wang, Hairong; Sun, Yupeng; Zhang, Lantong; Jia, Qingzhong

doi:10.3390/molecules24193470

Cited by 6 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This and the UV data correspond to farrerol ( Supplementary Materials ), identified in M. prasina [ 59 ]. Yin, Jintuo et al (2019) presented data that support to our findings [ 61 ]. Several of the very minor peaks appeared to have a farrerol aglycone component, based on the prominent m / z 301 ion in positive ion MS.…”

Section: Resultssupporting

confidence: 90%

Seasonal Chemical Evaluation of Miconia chamissois Naudin from Brazilian Savanna

et al. 2022

View full text Add to dashboard Cite

Miconia chamissois Naudin is a species from the Cerrado, which is being increasingly researched for its therapeutic potential. The aim of this study was to obtain a standardized extract and to evaluate seasonal chemical variations. Seven batches of aqueous extracts from leaves were produced for the standardization. These extracts were evaluated for total solids, polyphenol (TPC) and flavonoid content (TFC), vitexin derivative content, antioxidant activity; thin-layer chromatography (TLC), and high-performance liquid chromatography (HPLC) profiles were generated. For the seasonal study, leaves were collected from five different periods (May 2017 to August 2018). The results were correlated with meteorological data (global radiation, temperature, and rainfall index). Using chromatographic and spectroscopic techniques, apigenin C-glycosides (vitexin/isovitexin) and derivatives, luteolin C-glycosides (orientin/isoorientin) and derivatives, a quercetin glycoside, miconioside B, matteucinol-7-O-β-apiofuranosyl (1 → 6) -β-glucopyranoside, and farrerol were identified. Quality parameters, including chemical marker quantification by HPLC, and biological activity, are described. In the extract standardization process, all the evaluated parameters showed low variability. The seasonality study revealed no significant correlations (p < 0.05) between TPC or TFC content and meteorological data. These results showed that it is possible to obtain extracts from M. chamissois at any time of the year without significant differences in composition.

show abstract

Section: Resultssupporting

confidence: 90%

Seasonal Chemical Evaluation of Miconia chamissois Naudin from Brazilian Savanna

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Identified pathologically by angiogenesis, inflammation, and synovial hyperplasia in the synovial membrane that results in pannus formation accompanied by bone loss and extreme cartilage (Rutherford et al, 2017). Yin et al conducted the pharmacokinetic study of the farrerol in rat and in the microsomes using the UHPLC-Q-TOF-MS/MS (Yin et al, 2019). Total 42 metabolites such as bile (20), plasma (12), urine (34), faces (36) were found in the rats.…”

Section: Discussionmentioning

confidence: 99%

“…In hepatic tissue microsomes found the 15 metabolites. The major metabolic processes included deoxygenation, oxidation, sulfate conjugation, demethylation, and glucuronide conjugation and other less appropriate pathways include the conjugation of glucose, ketonization, conjugation of N-acetylcysteine, methylation, and N-acetylation (Yin et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Farrerol ameliorate adjuvant‐induced ankle injury via alteration of PPAR‐γ signal pathway

2021

View full text Add to dashboard Cite

This study evaluated the anti-inflammatory activity against lipopolysaccharide (LPS)mediated mouse macrophages (in vitro) and assessed the protective effect of farrerol on arthritis caused by complete freund adjuvant (CFA) in rats. For the evaluation of the pharmacological effect of farrerol on the activity of nitric oxide (NO) and cyclooxygenase, pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factorα (TNFα), and interleukin-1β, RAW 264.7 cells were used. A 0.1 ml CFA was injected subcutaneously for the induction of arthritis. The paw volume, body weight and arthritic score were estimated at regular intervals. Pro-inflammatory cytokines, inflammatory mediators, and antioxidant parameters were also estimated. Farrerol suppressed NO production and COX-catalyzed prostaglandin (PGE 2 ) in RAW 264.7. Farrerol also downregulated the p-p65, p-IκBα expression and upregulated the PPARγ expression in RAW 264.7 cells. Treatment of farrerol increased body weight substantially, and reduced paw edema and arthritic score. Farrerol treatment also significantly improved the level of hemoglobin (Hb), count of red blood cells (RBC), and decreased the rate of erythrocyte sedimentation (ESR), white blood cell (WBC) parameters, while the generation of pro-inflammatory cytokines inhibited. Together, farrerol also suppressed the pro-inflammatory cytokines TNFα, IL-6, and IL-1β. Obtained results directed that the farrerol exerted its therapeutic effect against CFA-induced arthritic rats through anti-inflammatory mechanism by regulation of the PPARγ. Practical applicationsIncrease the arthritis disease worldwide day-by-day. The current research study showed the anti-arthritic effect of farrerol (flavonoid phytoconstituent) of Rhododendron dauricum Linn. In this study, farrerol considerably inhibited the NF-κB to show the anti-arthritic effect. The finding showed the potential effect against acute and chronic inflammation via inhibition of inflammatory mediators and oxidative stress. The result suggests the anti-inflammatory and antioxidant effect of farrerol. On the basis of result, we can say that farrerol can be the beneficial drug to treat the arthritis.

show abstract

“…Epidemiology and molecular biology studies have shown that flavonoids can reduce the risk of cardiovascular disease in the diet, and that their biological functions may be related to antioxidant effects ( Dludla et al, 2017 ). Farrerol is the main ingredient isolated from the traditional Chinese herbal medicine Manshanhong ( Yin et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro

Wang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling.

show abstract

A Complete Study of Farrerol Metabolites Produced In Vivo and In Vitro

Cited by 6 publications

References 40 publications

Seasonal Chemical Evaluation of Miconia chamissois Naudin from Brazilian Savanna

Seasonal Chemical Evaluation of Miconia chamissois Naudin from Brazilian Savanna

Farrerol ameliorate adjuvant‐induced ankle injury via alteration of PPAR‐γ signal pathway

Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro

Contact Info

Product

Resources

About